Terms: = Kidney tumors AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Diagnosis
114 results:
1. Papillary Renal Cell Carcinoma: Evolving Classification by Combined Morphologic and Molecular Means.
Przybycin CG
Adv Anat Pathol; 2024 May; 31(3):147-156. PubMed ID: 38329413
[TBL] [Abstract] [Full Text] [Related]
2. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
[No Abstract] [Full Text] [Related]
3. Referral patterns and genetic testing outcomes in a contemporary hereditary renal cancer clinic.
McFadden J; Hardesty J; Schroeder C; Vance GH; Boris RS
Urol Oncol; 2024 Mar; 42(3):72.e19-72.e25. PubMed ID: 38267302
[TBL] [Abstract] [Full Text] [Related]
4. Update on Selected High-grade Renal Cell Carcinomas of the kidney: FH-deficient, ALK-rearranged, and Medullary Carcinomas.
Chen YB
Adv Anat Pathol; 2024 Mar; 31(2):118-125. PubMed ID: 38145398
[TBL] [Abstract] [Full Text] [Related]
5. The use of Clinicopathological, immunohistochemistry and molecular detection in the diagnosis of fumarate hydratase-deficient uterine leiomyomas.
Zhang X; Wang C; Shen D
Pathol Res Pract; 2024 Jan; 253():154916. PubMed ID: 38029712
[TBL] [Abstract] [Full Text] [Related]
6. Genomic alterations and diagnosis of renal cancer.
Zhang X; Bolck HA; Rupp NJ; Moch H
Virchows Arch; 2024 Feb; 484(2):323-337. PubMed ID: 37999735
[TBL] [Abstract] [Full Text] [Related]
7. Advanced fumarate hydratase-deficient renal cell carcinoma responding to combination immune checkpoint inhibitors.
Howells E; Wigston L; Mackie G; Tran B; Nott L
Can J Urol; 2023 Jun; 30(3):11558-11561. PubMed ID: 37344468
[TBL] [Abstract] [Full Text] [Related]
8. [Fumarate hydratase deficient uterine leiomyoma: a clinicopathological and molecular analysis of 80 cases].
Wang XX; Liu Y; Liu LC; Wang YX; Yang J; Hu AJ; Zhang B; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2023 Jun; 52(6):574-579. PubMed ID: 37263921
[No Abstract] [Full Text] [Related]
9. Reporting on FH-deficient renal cell carcinoma using circulating succinylated metabolites.
Bezwada D; Brugarolas J
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37259915
[TBL] [Abstract] [Full Text] [Related]
10. Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma.
Zheng L; Zhu ZR; Sneh T; Zhang WT; Wang ZY; Wu GY; He W; Qi HG; Wang H; Wu XY; Fernández-García J; Abramovich I; Xu YZ; Zhang J; Gottlieb E
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37053010
[TBL] [Abstract] [Full Text] [Related]
11. [Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis].
Wang Y; Hou MY; Fu Y; Meng K; Wu HY; Chen J; Xu YM; Shi J; Fan XS
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):358-363. PubMed ID: 36973196
[No Abstract] [Full Text] [Related]
12. [FH (Fumarate Hydratase)-deficient renal cell carcinoma: A case report].
Allaume P; Kammerer-Jacquet SF; Papadopoulos S; Rioux-Leclercq N
Ann Pathol; 2023 Sep; 43(5):417-420. PubMed ID: 36822902
[TBL] [Abstract] [Full Text] [Related]
13. Low-grade oncocytic tumour (LOT) of the kidney is characterised by GATA3 positivity, FOXI1 negativity and mTOR pathway mutations.
Chen T; Peng Y; Lei T; Wu C; Wang H; Shi Y
Pathol Oncol Res; 2023; 29():1610852. PubMed ID: 36816543
[No Abstract] [Full Text] [Related]
14. Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinoma.
Mannan R; Wang X; Bawa PS; Chugh S; Chinnaiyan AK; Rangaswamy R; Zhang Y; Cao X; Smith SC; Trpkov K; Williamson SR; Sangoi AR; Mohanty S; McKenney JK; Gupta S; Magi-Galluzzi C; Argani P; Osunkoya AO; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Hum Pathol; 2023 Apr; 134():102-113. PubMed ID: 36581128
[TBL] [Abstract] [Full Text] [Related]
15. kidney tumors associated with germline mutations of FH and SDHB show a CpG island methylator phenotype (CIMP).
Ricketts CJ; Killian JK; Vocke CD; Wang Y; Merino MJ; Meltzer PS; Linehan WM
PLoS One; 2022; 17(12):e0278108. PubMed ID: 36455002
[TBL] [Abstract] [Full Text] [Related]
16. [Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma].
Rare Kidney Cancer Collaborative Group, Genitourinary Cancer Committee, China Anti-Cancer Association
Zhonghua Wai Ke Za Zhi; 2022 Nov; 60(11):961-968. PubMed ID: 36323576
[TBL] [Abstract] [Full Text] [Related]
17. GATA3 aids in distinguishing fumarate hydratase-deficient renal cell carcinoma from papillary renal cell carcinoma.
Liu Y; Dong Y; Gu Y; Xu H; Fan Y; Li X; Dong L; Zhou L; Yang X; Wang C
Ann Diagn Pathol; 2022 Oct; 60():152007. PubMed ID: 35841867
[TBL] [Abstract] [Full Text] [Related]
18. [Analysis of phenotype and FH gene variation in a pedigree affected with hereditary leiomyomatosis and renal cell carcinoma syndrome].
Guo Y; Wang L; Xu Z; Bai Y; Wang W; Wu H; Sun Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2022 May; 39(5):494-498. PubMed ID: 35598264
[TBL] [Abstract] [Full Text] [Related]
19. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.
Anderson WJ; Tsai HK; Sholl LM; Hirsch MS
Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731
[No Abstract] [Full Text] [Related]
20. Uterine leiomyoma with fumarate hydratase deficiency: A case report.
Huang Y; Zhou Y; Chen X; Fang Q; Cai H; Xie M; Xing Y
Medicine (Baltimore); 2021 Dec; 100(49):e28142. PubMed ID: 34889279
[TBL] [Abstract] [Full Text] [Related]
[Next]
